



Final Appraisal Recommendation
Advice No: 1018 – July 2018

Telotristat ethyl (Xermelo®) 250 mg film-coated tablets

Submission by Ipsen Ltd

Recommendation of AWMSG

Telotristat ethyl (Xermelo®) is recommended as an option for restricted use within NHS Wales.

Telotristat ethyl (Xermelo®) is licensed for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.

Telotristat ethyl (Xermelo®) is restricted for use for the treatment of carcinoid syndrome diarrhoea in adults who are inadequately controlled by SSA therapy and who experience an average of four or more bowel movements a day.

Telotristat ethyl (Xermelo®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that telotristat ethyl (Xermelo®) satisfied the AWMSG criteria for ultra-orphan status.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2037), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Date of first issue	July 2018
Last reviewed	December 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1018:
Telotristat ethyl (Xermelo®) 250 mg film-coated tablets. July 2018.